CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD.

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CNE000000Q94

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-22 EDT			5-day change	1st Jan Change
21.64 ^CNY	-1.41%		-7.44%	+16.34%

11:01am	CR Double-Crane Pharmaceutical's Unit Gets Nod to Market Schizophrenia Drug	MT
05-08	CR Double-Crane Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride Injection	MT

China Resources Double-Crane Pharmaceutical Co., Ltd. Approves to Nominates Zhang Kejian as Independent Director

January 25, 2016

China Resources Double-Crane Pharmaceutical Co., Ltd. approved the proposal of nominating Zhang Kejian as Independent Director at directorate meeting held on January 22, 2016.

Latest news about China Resources Double-Crane Pharmaceutical Co.,Ltd.

CR Double-Crane Pharmaceutical's Unit Gets Nod to Market Schizophrenia Drug	05:01am	MT
CR Double-Crane Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride Injection	05-08	MT
CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2%	04-26	MT
CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication	04-26	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
CR Double-Crane Pharmaceutical Gets Nod to Trial Semaglutide Injection	04-16	MT
CR Double-Crane Pharma Unit Receives Approval for Epilepsy Drug	03-26	MT
CR Double-Crane Pharma's 2023 Profit Jumps 13%, Operating Income Climbs 6%	03-22	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. Proposes Cash Dividend	03-21	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
CR Double-crane Pharmaceutical Gets Nod to Market Doxazosin Mesylate Tablets	03-12	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group Co., Ltd. for CNY3.1 billion.	02-25	CI
CR Double-Crane Pharma Gets Nod for Apixaban Tablets; Unit's Clozapine Orally Disintegrating Tablets Gets Greenlight for Proposed Amendments	02-20	MT
CR Double-Crane Pharma's Unit Gets Nod to Market Lithium Carbonate Drug Ingredient	02-08	MT
CR Double-Crane Pharmaceutical's Unit Gets Nod to Raise Strength of Viagra Drug	01-31	MT
China Includes CR Double-Crane Pharmaceutical's Two Drugs in List of Insurance-Backed Drugs	12-14	MT
CR Double-Crane Pharma Unit Gets Nod to Amend Sodium Lactate Ringer Injection's Details	12-12	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) dropped from Shanghai Stock Exchange 180 Value Index	12-08	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) dropped from SSE 180 Index	12-08	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. completed the acqyusution 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd.	11-02	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
CR Double-Crane Pharma to Buy 90% Stake in Local Peer For 260 Million Yuan	23-09-28	MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire an 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd for CNY 260 million	23-09-27	CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
CR Double-Crane Pharma Gets Regulatory Nod to Amend Instructions for Lansoprazole for Injection	23-08-09	MT

Chart China Resources Double-Crane Pharmaceutical Co.,Ltd.

Duration

Period

Chart China Resources Double-Crane Pharmaceutical Co.,Ltd.

More charts

CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The Company's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The Company distributes its products mainly in domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-26 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for China Resources Double-Crane Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.64 CNY

Average target price

25.58 CNY

Spread / Average Target

+18.21%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD.	+16.34%	3.1B
ELI LILLY AND COMPANY	+38.96%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.22%	369B
MERCK & CO., INC.	+20.23%	332B
ABBVIE INC.	+2.78%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	+0.12%	168B

Other Pharmaceuticals